## National Institute for Health and Care Excellence IP1782 Transcutaneous electrical stimulation of the trigeminal nerve for ADHD

IPAC date: 13th October 2022

Com	Consultee name and	Sec. no.	Comments	Response
. no.	organisation			Please respond to all comments
1	Consultee 1	1.2		Thank you for your comment.
	Clinical researcher			Section 1.2 of the guidance was amended to:
				'Further research could be in the form of multicentre, sham-controlled (or other suitable comparator) trials and should include details of patient selection, treatment protocols, adherence and long-term outcomes.'
2	Consultee 1	2.2	I would add "and second-line pharmacological	Thank you for your comment.
	Clinical researcher		non-stimulants such as Atomoxetine"	Section 2.2 of the guidance was amended to:
				'Pharmacological treatment includes central nervous system stimulants such as methylphenidate and amphetamines, and non-stimulants such as atomoxetine.'

Com . no.	Consultee name and organisation	Sec. no.	Comments	Response Please respond to all comments
3	Consultee 1 Clinical researcher	2.4	I would add "associated with selective maintenance of attention and arousal"	Thank you for your comment.  Section 2.4 of the guidance was amended to:  'The mechanism of action is not completely understood. The trigeminal nerve connects to regions of the brain that may be associated with selective maintenance of attention and arousal, and it is thought that its stimulation improves the symptoms of ADHD'
4	Consultee 1 Clinical researcher	Overview	I would change this to "a test of interference inhibition" or "cognitive inhibition"	Thank you for your comment.  The description of the Flanker test was amended to 'a test of interference inhibition'.
5	Consultee 1 Clinical researcher	Overview	The BRIEF is a behavioural questionnaire and not a cognitive measure	Thank you for your comment.  BRIEF outcomes were moved to the behavioural section of the overview.

<sup>&</sup>quot;Comments received in the course of consultations carried out by NICE are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that NICE has received, and are not endorsed by NICE, its officers or advisory committees."